Press release from the issuing company
EMA reduces submission fees by over 50 percent with the use of Docu-Proof an Automated Text Comparison Software
Ghent, Belgium – Global Vision, the industry leader in the development of automated proofreading solutions, announces that Docu-Proof has met compliance requirements as a text comparison software solution by the European Medicines Agency (EMA) for pharmaceutical companies using parallel distribution methods of medicinal products.
For pharmaceutical companies, deployment of Docu-Proof would result in cost savings of 290 euros per submission versus performing manual comparisons. Currently, the annual update or change notification fee without using an approved text comparison solution is 570 euros per submission. With Docu-Proof the annual fee is reduced to 280 euros.
“We have worked diligently with our pharmaceutical customers to ensure that Docu-Proof meet the EMA compliance requirements,” explained Peter Muller, VP Business Development for Europe, Middle East, Africa and Asia at Global Vision. “Docu-Proof exceeds the EMA requirements with additional technology such as medical spell-check and complex table handling.”
“For additional cost savings, Docu-Proof’s concurrent licensing allows users to share the software across multiple locations,” continued Peter Muller.
To learn more about the new program from the EMA and how current customers are already benefitting from Global Vision Solutions please visit us at The Total Processing & Packaging Exhibition, booth L41, 04-06 June in Birmingham United Kingdom, or by email at [email protected].
Meeting Compliance
Docu-Proof has been recognized as a text-comparison software that preserves data integrity of the documents and is designed to detect deviations between the package leaflet and the text of the annexes:
EMA Deviation measurement requirements
© 2024 WhatTheyThink. All Rights Reserved.